Daniel Janney Sells 37,895 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 37,895 shares of the business’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Janney also recently made the following trade(s):

• On Thursday, February 26th, Daniel Janney sold 7,741 shares of Krystal Biotech stock. The stock was sold at an average price of $275.63, for a total value of $2,133,651.83.
• On Wednesday, February 25th, Daniel Janney sold 700 shares of Krystal Biotech stock. The shares were sold at an average price of $275.00, for a total transaction of $192,500.00.
• On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The stock was sold at an average price of $268.34, for a total transaction of $3,709,800.50.

Krystal Biotech Price Performance

Krystal Biotech stock traded up $3.86 during midday trading on Thursday, hitting $276.36. The company’s stock had a trading volume of 215,358 shares, compared to its average volume of 317,968. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $298.30. The company has a 50-day moving average price of $268.29 and a two-hundred day moving average price of $213.42. The company has a market cap of $8.08 billion, a price-to-earnings ratio of 40.34 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on KRYS shares. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Jefferies Financial Group raised their price target on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Bank of America boosted their price target on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Chardan Capital increased their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group raised their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a report on Friday, January 30th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and a consensus price target of $326.25.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its holdings in shares of Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC increased its position in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares during the last quarter. Empowered Funds LLC bought a new position in Krystal Biotech in the 1st quarter valued at approximately $218,000. Finally, CWM LLC boosted its position in Krystal Biotech by 7.2% in the second quarter. CWM LLC now owns 1,583 shares of the company’s stock valued at $218,000 after buying an additional 107 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.